Oral Anti-Inflammatory Clears Phase 2 Without Liver Risk; Rezera Sets $200M IPO for NLRP3 Inhibitor
· techtimes.com · popularity 20/100 · 0 similar stories today
Read the original at techtimes.com →
Summary
Rezera's oral NLRP3 inhibitor cleared Phase 2 without the liver toxicity that halted MCC950, clearing the path for a $200M IPO and Phase 3 PAD trial.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.